RT Journal Article
SR Electronic
T1 SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T-cell receptors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20107813
DO 10.1101/2020.05.20.20107813
A1 Shomuradova, Alina S.
A1 Vagida, Murad S.
A1 Sheetikov, Savely A.
A1 Zornikova, Ksenia V.
A1 Kiryukhin, Dmitry
A1 Titov, Aleksei
A1 Peshkova, Iuliia O.
A1 Khmelevskaya, Alexandra
A1 Dianov, Dmitry V.
A1 Malasheva, Maria
A1 Shmelev, Anton
A1 Serdyuk, Yana
A1 Bagaev, Dmitry V.
A1 Pivnyuk, Anastasia
A1 Shcherbinin, Dmitrii S.
A1 Maleeva, Alexandra V.
A1 Shakirova, Naina T.
A1 Pilunov, Artem
A1 Malko, Dmitry B.
A1 Khamaganova, Ekaterina G.
A1 Biderman, Bella
A1 Ivanov, Alexander
A1 Shugay, Mikhail
A1 Efimov, Grigory A.
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.20.20107813.abstract
AB Understanding the hallmarks of the adaptive immune response to SARS-CoV-2 is critical for fighting the COVID-19 pandemic. We assessed the antibody and T-cell reactivity in COVID-19 convalescent patients and healthy donors sampled both prior to and during the pandemic. The numbers of SARS-CoV-2-specific T cells were increased in healthy donors examined during COVID-19. Combined with the absence of symptoms and humoral response across that group, this finding suggests that some individuals might be protected by T-cell cross-reactivity. In convalescent patients we observed public and diverse T-cell response to SARS-CoV-2 epitopes, revealing T-cell receptor motifs with germline-encoded features. Bulk CD4+ and CD8+ T-cell responses to Spike glycoprotein were mediated by groups of homologous T-cell receptors, some of them shared across multiple donors. Overall, our results demonstrate that T-cell response to SARS-CoV-2, including the identified set of specific T-cell receptors, can serve as a useful biomarker for surveying viral exposure and immunity.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthe study did not involve a clinical trialFunding StatementMikhail Shugay was supported by RFBR grant No 19-34-70011. Alexander Ivanov was supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075-15-2019-1660].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by by the National Research Center for Hematology ethical committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTCR sequencing data was deposited to the VDJdb database (vdjdb.cdr3.net) and attached to this article as Extended data tables https://www.vdjdb.cdr3.net